Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma

Gopal, Ajay K.; Gooley, Ted; Rajendran, Joseph G.; Pagel, John M.; Fisher, Darrell R.; Maloney, David G.; Appelbaum, Frederick R.; Cassaday, Ryan D.; Shields, Andrew; Press, Oliver W.

doi:10.1016/j.bbmt.2014.02.004

Cited by 23 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials assessing the efficacy of concurrent fludarabine and high-dose RIT 57 or etoposide, cyclophosphamide, and RIT 58 have validated the promise of these combinations. An alternative approach is to combine RIT targeting one antigen with unlabeled monoclonal antibodies targeting a different antigen, as has been done with 90 Y-epratuzumab tetraxetan (anti-CD22) combined with veltuzumab (anti-CD20).…”

Section: Rit Of Haematological Malignanciesmentioning

confidence: 99%

Radioimmunotherapy of human tumours

et al. 2015

Self Cite

View full text Add to dashboard Cite

PREFACE Eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Such radioimmunotherapy (RIT) permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering, and radiochemistry in the last decade has markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types.

show abstract

Section: Rit Of Haematological Malignanciesmentioning

confidence: 99%

Radioimmunotherapy of human tumours

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conventional regimens comprised either carmustine, etoposide, cytarabine, and melphalan (BEAM); busulfan, melphalan, and thiotepa (BuMelT); or cyclophosphamide with or without etoposide in combination with 12 Gray of total body irradiation (TBI), as previously documented (25, 26). RIT was given either alone or with increasing doses of fludarabine or with cyclophosphamide and etoposide (27-29). …”

Section: Methodsmentioning

confidence: 99%

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Cowan

Stevenson

Cassaday

et al. 2016

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission following induction chemotherapy with the best results for patients in complete remission (CR). We hypothesized that evaluation of MRD prior to ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011, with pretransplant MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11;14) by PCR, or positive flow cytometry from blood or bone marrow was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached with 82% survival at 5 years, while for the MRD-positive patients was 3.01 years (hazard ratio [HR] 4.04, p = 0.009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75 % PFS at 5 years, while for MRD-positive patients was 2.38 years (HR 3.69, p = 0.002). MRD positivity is independently associated with poor outcome following ASCT for MCL patients in CR.

show abstract

“…This agent is administered to patients with metastatic colorectal cancer to view the extent of metastatic development (39-42); (ii) Ibritumomab tiuxetan is a murine MAB which is labeled with yttrium 90 or Indium 111. These radioactive agents are used for the treatment of patients with non-Hodgkin's lymphoma and often used together with Rituximab which was discussed above (43-45); (iii) Capromab pendetide, a murine MAB, targets prostate membranes and is used to diagnose prostate cancer or determine the extent of cancer eradication following prostatectomy (46)(47)(48); (iv) Tositumomab is a MAB labeled with iodine 131 and is used to treat patients with non-Hodgkin's lymphoma who are unresponsive to standard chemotherapy (49)(50)(51)(52) .…”

Section: Antitumor Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

Monoclonal Antibodies for the Treatment of Cancer

Pento

2017

View full text Add to dashboard Cite

Abstract.Cancer metastasis is responsible for most of the morbidity and mortality associated with cancer. Cancer metastatic progression is a multiple step process which includes enhanced cell proliferation, release of proteolytic enzymes, cell motility and invasion, angiogenesis and establishment of a supportive microenvironment at the sites of metastatic growth (1, 2).Traditional cancer therapy has focused on removal or destruction of tumour cells by surgery, radiation and rather nonselective types of chemotherapy. Surgery and radiation are often effective with tumours which are localized and have not metastasized to multiple sites throughout the body. Chemotherapy appears to be most effective in the treatment of metastatic cancer; however, typical chemotherapeutic agents such as cisplatin, methotrexate, vincristine, 5-fluorouracil among many others, focus on rapidly growing tissues since cancer cells are relatively rapidly growing. Thus, cancer chemotherapy often results in a high incidence of unwanted and damaging side-effects in rapidly-dividing normal tissues, such as blood cells and cells lining gastrointestinal tract.With a greater understanding of cellular chemistry and genomics during the past twenty years, cellular targets that are unique to cancer cells have been identified and chemotherapeutic agents which specifically bind to, destroy or otherwise inactivate these unique cellular targets have been developed. These agents which impede these unique or overexpressed cancer targets tend to be more selective, -thus more effective with fewer side-effects than traditional, nonselective chemotherapy. They target critical checkpoints which are often overexpressed on rapidly growing and malignant cancer cells, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and tyrosine kinase. Therefore, cancer Immunotherapy is an exciting and relatively new method to selectively block critical checkpoints in the process of cancer development (3, 4).

show abstract

Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma

Cited by 23 publications

References 33 publications

Radioimmunotherapy of human tumours

Radioimmunotherapy of human tumours

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Monoclonal Antibodies for the Treatment of Cancer

Contact Info

Product

Resources

About